{{Short description|Group of stereoisomers}} {{Drugbox | Verifiedfields = | verifiedrevid = | IUPAC_name = [1-[(1-Methylpiperidin-2-yl)methyl]-1''H''-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone | image = AB-005.png | image_class = skin-invert-image | width = 200
<!--Clinical data--> | tradename = | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_US = <!-- A / B / C / D / X --> | pregnancy_category = | legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> | legal_CA = Schedule II | legal_DE = NpSG | legal_UK = Class B | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> | legal_status = | routes_of_administration =
<!--Pharmacokinetic data--> | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =
<!--Identifiers--> | CAS_number_Ref = {{cascite|correct|CAS}} | CAS_number = 895155-25-6 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = TPY5M47AYQ | ATC_prefix = | ATC_suffix = | PubChem = 11537652 | DrugBank_Ref = | DrugBank = | ChemSpiderID_Ref = | ChemSpiderID = 9712433 | ChEMBL = 571330
<!--Chemical data--> | C=23 | H=32 | N=2 | O=1 | smiles = CC1(C(C1(C)C)C(=O)C2=CN(C3=CC=CC=C32)CC4CCCCN4C)C | StdInChI = 1S/C23H32N2O/c1-22(2)21(23(22,3)4)20(26)18-15-25(19-12-7-6-11-17(18)19)14-16-10-8-9-13-24(16)5/h6-7,11-12,15-16,21H,8-10,13-14H2,1-5H3 | StdInChIKey = MOBWRRIAIHYXLB-UHFFFAOYSA-N }}
'''AB-005''' or '''[1-[(1-methylpiperidin-2-yl)methyl]-1''H''-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone''' is a designer drug offered by online vendors as a cannabimimetic agent. The structure and pharmacological activity of AB-005 was published in 2010, prior to its commercial availability in 2012, where it was reported to have high affinity for both CB1 (''K''<sub>i</sub> = 5.5 nM) and CB2 receptors (''K''<sub>i</sub> = 0.48 nM).<ref>{{cite journal | vauthors = Frost JM, Dart MJ, Tietje KR, Garrison TR, Grayson GK, Daza AV, El-Kouhen OF, Yao BB, Hsieh GC, Pai M, Zhu CZ, Chandran P, Meyer MD | display-authors = 6 | title = Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity | journal = Journal of Medicinal Chemistry | volume = 53 | issue = 1 | pages = 295–315 | date = January 2010 | pmid = 19921781 | doi = 10.1021/jm901214q }} </ref> AB-005 features groups found in other previously reported synthetic cannabinoids: the tetramethylcyclopropane group of UR-144 and XLR-11 as well as the (1-methyl-2-piperidinyl)methyl substituent of AM-1248 and AM-1220. No information regarding the in vivo activity of AB-005 has been published, and only anecdotal reports are known of its psychoactivity in humans.
==Legal status== In 2013, psychoactive products in New Zealand containing this drug were given interim approval under psychoactive substances legislation.<ref>{{cite web | url = http://www.health.govt.nz/our-work/regulation-health-and-disability-system/psychoactive-substances/interim-product-approvals | title = Interim Product Approvals | publisher = Ministry of Health | access-date = 2 January 2013 | archive-url = https://web.archive.org/web/20130821055156/http://www.health.govt.nz/our-work/regulation-health-and-disability-system/psychoactive-substances/interim-product-approvals | archive-date = 21 August 2013 | url-status = dead }}</ref>
== See also == * A-834,735 * AB-001 * JWH-018 * FUB-144
== References == {{reflist}}
{{Cannabinoids}}
Category:Cannabinoids Category:Designer drugs Category:Tetramethylcyclopropanoylindoles Category:Piperidines